ENCePP Steering Group
The ENCePP Steering Group (SG) was established in 2010 to oversee the mid to long-term implementation of ENCePP. The Steering Group consists of 20 members with a balance of expertise and experience (regulatory, conduct of pharmacoepidemiological studies, patients, healthcare professionals, ethical issues). Six members of the Steering Group are elected representatives from the ENCePP Plenary. From 2014 onwards, the term of service of the Steering Group is three years.
The ENCePP Steering Group defines and safeguards the objectives and principles of ENCePP and decides on operational tasks of the network. The Steering Group is the highest authority of ENCePP and thus is its final decision making body. It acts as adjudicator in case of discrepancies or complaints in the context of the ENCePP network.
Composition of the ENCePP SG 2024-2026
Name | Affiliation | Representing |
---|---|---|
Helga Gardarsdottir (Co-chair) | Utrecht University, the Netherlands | ENCePP partners |
Catherine Cohet (Co-chair) | European Medicines Agency, Data Analytics and Methods Task Force, the Netherlands | EMA |
Alejandro Arana | RTI Health Solutions, Spain | ENCePP partners |
Annalisa Landi | TEDDY European Network of Excellence for Paediatric Clinical Research, Italy | ENCePP partners |
Christos Kontogiorgis | Democritus University of Thrace, Laboratory of Hygiene and Environmental Protection, Greece | ENCePP partners |
Marco Tuccori | University hospital of Pisa, Unit of adverse drug reactions monitoring UADRM, Italy | ENCePP partners |
Vera Ehrenstein | Aarhus University, Department of Clinical Epidemiology, Denmark | ENCePP partners |
Annette Cleveland Nielsen | Danish Medicines Agency, Denmark | HMA |
Carla Torre | University of Lisbon, Portugal | CHMP, MWP |
Frauke Naumann-Winter | Federal Institute for Drugs and Medical Devices, Germany | COMP |
Hedvig Marie Egeland Nordeng | Norwegian Institute Of Public Health | PRAC |
Iryna Vlasenko | European Chapter of the International Diabetes Federation, Belgium | PCWP |
Arnold K. Chan | TriNetX, USA | ISPE |
Gianluca Trifirò | University of Verona, Department of Diagnostics and Public Health, Italy | ISoP |
Laura Pizzi | International Society for Pharmacoeconomics and Outcomes Research, USA | ISPOR |
Craig Simon | Health Canada, Canada | Health Canada |
Hui-Lee Wong | U.S. Food and Drug Administration, USA | FDA |
Gianmario Candore | Bayer, Germany | Industry |
Nadia Amaouche | European Medicines Agency, Human Medicines Division, the Netherlands | EMA |
Thomas Goedecke | European Medicines Agency, Human Medicines Division, the Netherlands | EMA |
EMA | European Medicines Agency |
HMA | Heads of Medicines Agencies |
CHMP | Committee for Medicinal Products for Human Use |
COMP | Committee for Orphan Medicinal Products |
PRAC | Pharmacovigilance Risk Assessment Committee |
PCWP | Patients' and Consumers' Working Party |
ISPE | International Society for Pharmacoepidemiology |
ISoP | International Society of Pharmacovigilance |
ISPOR | International Society for Pharmacoeconomics and Outcomes Research (The professional society for health economics and outcomes research) |
FDA | Food and Drug Administration |
MWP | Methodological Working Party |